CT
Crosslink Therapeutics Inc.
SEC filingPharmaceuticals · Boston, MA
Amount raised$5.5Msold at filing
Total offering$5.5M
Investors in the raise8count reported to the SEC
FiledOct 20, 2026first sale Oct 8, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Ronald D. Seidel, IIIExecutive Officer, Director
Andrew KingDirector
Lou TartagliaDirector
Rodolfo ChaparroDirector
David FallaceDirector
Cameron GallagherDirector
Executive officers, directors and promoters as listed on the Form D.